1. Review the accumulated clinical experience in treating IPF with antifibrotics.
2. Review the current evidence behind the use of antifibrotic agents in SSc-ILD.
3. Critically evaluate the medical benefits with respect to potential side effects and increase in medical costs associated with the use of antifibrotic agents in SSc.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation